Lexeo Therapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Lexeo and Cornell University executed a Third Amendment (dated 6/9/2026) to correct a scrivener's error in the Second Amendment (effective 12/22/2025). The correction clarifies that only Paragraph 3.1(a)—not the entire Paragraph 3.1—was modified. Paragraph 3.1(a) specifies license fees, data transfer fees, and annual data fees, all redacted as [***], with no substantive changes to the underlying agreement terms.
Why this rating
Purely ministerial correction of a scrivener's error; no substantive economic or operational changes disclosed. Fee amounts redacted; no new material obligations imposed.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.